MYGN · XBRL financial data

Myriad Genetics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MYGN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	192	197*	202	212	213	211*	196	213	206	210*	200	191
Cost of goods and services sold	58	62*	65	64	64	60*	62	61	62	63*	63	64
Gross profit	—	135*	138	147	150	151*	134	152	144	147*	138	127
Research and development	24	21*	25	27	29	32*	28	26	28	26*	27	25
Selling, general and administrative	136	144*	141	145	139	—	—	—	—	—	—	—
General and administrative	—	year only	71	72	69	64*	67	67	68	56*	62	58
Total operating expenses	—	year only	166	184	170	190*	163	481	167	153*	168	166
Operating income (loss)	(60)	(31)*	(28)	(37)	(20)	(39)*	(29)	(329)	(23)	(6)*	(31)	(39)
Interest income	1	1*	1	0	0	0*	0	0	1	1*	1	0
Interest expense	1	1*	1	1	1	1*	1	2	4	4*	4	4
Other income (expense)	(1)	(1)*	2	(0)	(1)	0*	0	(0)	0	0*	0	0
Income tax expense (benefit)	0	(1)*	0	(1)	1	3*	(29)	(0)	1	(1)*	0	1
Net income (loss)	(61)	(31)*	(26)	(37)	(22)	(43)*	(0)	(331)	(27)	(8)*	(34)	(43)
Earnings per share, basic USD per share	(0.75)	(0.36)*	(0.29)	(0.41)	(0.24)	(0.47)*	0.00	(3.57)	(0.29)	(0.08)*	(0.36)	(0.46)
Earnings per share, diluted USD per share	(0.75)	(0.36)*	(0.29)	(0.41)	(0.24)	(0.47)*	0.00	(3.57)	(0.29)	(0.08)*	(0.36)	(0.46)
Weighted average shares, basic millions of shares	82	86*	90	91	91	91*	91	93	93	93*	94	95
Weighted average shares, diluted millions of shares	82	86*	90	91	91	91*	91	93	93	93*	94	95

Fiscal quarters (MYGN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	76	132	97	92	100	102	92	74	145	150	124	115
Marketable securities	10	9	7	5	0	0	—	—	—	—	—	—
Marketable securities, non-current	0	0	—	—	—	—	—	—	—	—	—	—
Accounts receivable	115	114	118	118	126	121	120	137	118	115	124	110
Inventory	25	22	25	26	26	28	28	29	32	31	28	31
Prepaid and other current assets	21	19	25	22	24	31	32	30	36	25	35	32
Total current assets	265	314	290	292	293	298	287	284	345	333	313	289
Property and equipment, net	121	119	119	116	115	117	114	113	111	114	112	109
Right-of-use asset	104	62	59	57	57	55	53	51	51	49	51	50
Goodwill	287	287	287	286	286	286	286	52	52	52	47	47
Total assets	1,149	1,147	1,111	1,085	1,081	1,028	1,006	677	728	707	674	639
Accounts payable	34	26	33	33	30	32	28	31	32	30	33	30
Accrued liabilities	158	114	99	98	111	119	112	101	108	97	91	93
Current portion of long-term debt	—	—	—	—	—	0	—	59	—	—	—	—
Total current liabilities	209	156	146	149	154	164	151	200	148	134	130	131
Long-term debt	39	39	39	39	39	40	59	0	120	120	120	121
Lease liability, non-current	145	97	94	91	91	88	87	86	85	83	84	83
Total liabilities	466	363	351	345	350	327	301	289	355	339	336	335
Accumulated deficit	(598)	(630)	(656)	(692)	(714)	(757)	(757)	(1,087)	(1,115)	(1,123)	(1,157)	(1,200)
Total stockholders' equity	683	783	760	741	732	701	705	388	373	368	337	304
Total liabilities and equity	1,149	1,147	1,111	1,085	1,081	1,028	1,006	677	728	707	674	639
Common shares outstanding (cover page) millions of shares	82	90	91	91	91	91	92	93	93	94	94	96

Fiscal quarters (MYGN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(61)	(31)*	(26)	(37)	(22)	(43)*	(0)	(331)	(27)	(8)*	(34)	(43)
Stock-based compensation	12	10*	12	15	12	11*	10	11	12	3*	7	7
Net cash from operating activities	(22)*	(55)*	(19)	3*	1*	7*	(16)	(14)*	21*	11*	(16)	(8)*
Net cash from investing activities	(3)*	(12)*	(7)	(6)*	8*	(6)*	(8)	(7)*	(6)*	(6)*	(7)	(3)*
Net cash from financing activities	(3)*	122*	(9)	2*	(3)*	2*	14	3*	56*	(8)*	(3)	2*
Net change in cash	(28)*	56*	(35)	(4)*	9*	2*	(11)	(17)*	71*	(4)*	(25)	(9)*

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Myriad Genetics	115	191	(8.3)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Arbutus Biopharma	19	1	(6)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Arvinas	88	0.5	(10)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
aTYR PHARMA	16	not reported	(9.4)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Iovance Biotherapeutics	111	99	(61)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122	38	10*	59.5M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.